Echo Therapeutics Inc fka ECTE

[SD1527]

These guys want to achieve AMEX listing and use that to springboard onto a more senior exchange. So, this makes $2 a pretty certain reality pending no unforeseen roadbumps to it gaining FDA approval for its Symphony product.

Were already up about $.50 since the beginning of December. Another $.30 would represent a very bullish move in recent months, but I think it could be achievable given the company's need to up-list.

I'd imagine that AMEX listing or better would be extremely helpful for Echo as it looks to secure financing and establish business relationships with leading global healthcare firms. The first product has multi-billion dollar potential and listing on a senior exchange would certainly give the company added credibility.

If I were the company, I'd be doing everything possible to boost PPS to >$2. Since these guys are considerably more intelligent than I, I think its pretty safe to say they're on it. Just my .02.